Trial Site Detail


Cobimetinib + MPDL3280A
A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors
Conditions: Solid Tumors
Trial Status:
Ongoing, but not recruiting


Dana Farber Cancer Institute

450 Brookline Ave     
Boston , MA 02215-5450


Principal Investigator:
George Demetri, MD
Tarsha Huftalen, RN, BSN 617-632-5117
Activation Status of this Site:
Notes about this Site:
Dana Farber Cancer Institute Website:



Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.